We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer's Humira Biosimilar Meets Primary Endpoint in Study
Read MoreHide Full Article
Pfizer, Inc. (PFE - Free Report) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar to AbbVie Inc.’s (ABBV - Free Report) Humira (adalimumab) approved for the treatment of patients with rheumatoid arthritis.
Pfizer’s three-month share price movement shows that the stock has significantly outperformed the Zacks classified Large Cap Pharma industry. Specifically, the company gained 0.2%, while the industry lost 4%.
Coming back to the latest news, REFLECTIONS B538-02 is a comparative safety and efficacy study on PF-06410293, in combination with methotrexate, compared with a combination of Humira and methotrexate, in patients with moderate-to-severe rheumatoid arthritis. Data from the study showed that the primary endpoint of the American College of Rheumatology 20 (ACR20) response rate was equivalent for PF-06410293 and Humira.
Humira, which is currently approved for several indications, generated sales of $14 billion in 2015, up 11.7% year over year.
We remind investors that Amgen, Inc.’s (AMGN - Free Report) biosimilar version of Humira, Amjevita, received FDA approval in Sep 2016. However, Amgen does not expect to launch Amjevita in 2017 due to an ongoing litigation with AbbVie.
Pfizer's biosimilar portfolio got a significant boost from the company’s Hospira acquisition in 2015. The company expects to launch Inflectra, a biosimilar version of Johnson & Johnson (JNJ - Free Report) and Merck’s blockbuster drug, Remicade, in the U.S. shortly. Inflectra is the first and only biosimilar monoclonal antibody (mAb) therapy, and the second biosimilar to be approved in the U.S.
Pfizer’s pipeline consists of eight distinct biosimilar molecules in mid- to late-stage development, apart from several others in earlier stages.
Pfizer believes that the market for biosimilars is huge and can grow to $17–$20 billion by 2020. In the third quarter of 2016, the company recorded biosimilar revenues of $83 million.
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Pfizer's Humira Biosimilar Meets Primary Endpoint in Study
Pfizer, Inc. (PFE - Free Report) announced positive top-line results from the comparative REFLECTIONS B538-02 study on its investigational compound, PF-06410293, a potential biosimilar to AbbVie Inc.’s (ABBV - Free Report) Humira (adalimumab) approved for the treatment of patients with rheumatoid arthritis.
Pfizer’s three-month share price movement shows that the stock has significantly outperformed the Zacks classified Large Cap Pharma industry. Specifically, the company gained 0.2%, while the industry lost 4%.
Coming back to the latest news, REFLECTIONS B538-02 is a comparative safety and efficacy study on PF-06410293, in combination with methotrexate, compared with a combination of Humira and methotrexate, in patients with moderate-to-severe rheumatoid arthritis. Data from the study showed that the primary endpoint of the American College of Rheumatology 20 (ACR20) response rate was equivalent for PF-06410293 and Humira.
Humira, which is currently approved for several indications, generated sales of $14 billion in 2015, up 11.7% year over year.
We remind investors that Amgen, Inc.’s (AMGN - Free Report) biosimilar version of Humira, Amjevita, received FDA approval in Sep 2016. However, Amgen does not expect to launch Amjevita in 2017 due to an ongoing litigation with AbbVie.
Pfizer's biosimilar portfolio got a significant boost from the company’s Hospira acquisition in 2015. The company expects to launch Inflectra, a biosimilar version of Johnson & Johnson (JNJ - Free Report) and Merck’s blockbuster drug, Remicade, in the U.S. shortly. Inflectra is the first and only biosimilar monoclonal antibody (mAb) therapy, and the second biosimilar to be approved in the U.S.
Pfizer’s pipeline consists of eight distinct biosimilar molecules in mid- to late-stage development, apart from several others in earlier stages.
Pfizer believes that the market for biosimilars is huge and can grow to $17–$20 billion by 2020. In the third quarter of 2016, the company recorded biosimilar revenues of $83 million.
PFIZER INC Price
PFIZER INC Price | PFIZER INC Quote
Zacks Rank & Key Picks
Pfizer currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Best Place to Start Your Stock Search
Today, you are invited to download the full list of 220 Zacks Rank #1 "Strong Buy" stocks – absolutely free of charge. Since 1988, Zacks Rank #1 stocks have nearly tripled the market, with average gains of +26% per year. Plus, you can access the list of portfolio-killing Zacks Rank #5 "Strong Sells" and other private research. See these stocks free >>